tiotropium high dose

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Asthma

Phase 3

Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma

CompletedNCT01277523

Boehringer IngelheimAsthma

Start: 2011-01-31End: 2013-10-31Updated: 2014-10-20

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma

CompletedNCT01634152

Boehringer IngelheimAsthma

Start: 2012-07-31End: 2015-05-31Updated: 2016-01-29

Related Papers

Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV<sub>1</sub>.

2019-07-1817 citations

Safety of tiotropium Respimat<sup>®</sup> in black or African-American patients with symptomatic asthma.

2019-07-022 citations

P45 Effect of tiotropium respimat® on seasonal asthma worsening in paediatric patients

2018-11-161 citations

P155 Safety of tiotropium respimat® add-on therapy in patients aged 6–17 years with symptomatic asthma

Thorax2016-11-151 citations

A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma

European Respiratory Journal2016-11-03106 citations

Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma

2016-09-011 citations

Safety of tiotropium Respimat® add-on therapy in patients aged 6-17 years with symptomatic asthma

2016-09-01